Head And Neck Cancer - Pipeline Review, H2 2015

Head And Neck Cancer - Pipeline Review, H2 2015

Code: GMDHC6824IDB | Published: Dec-2015 | Pages: 1011 | Global Markets Direct
Price :
$2,500.00
USD

* Required Fields

$2,500.00

Details

Head And Neck Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Head And Neck Cancer - Pipeline Review, H2 2015, provides an overview of the Head And Neck Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Head And Neck Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Head And Neck Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
4SC AG
AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
Advaxis, Inc.
Alchemia Limited
Altor BioScience Corporation
Ambrx, Inc.
Amgen Inc.
ANP Technologies, Inc.
arGEN-X BV
ArQule, Inc.
Ascenta Therapeutics, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
ATLAB Pharma SAS
AVEO Pharmaceuticals, Inc.
Bayer AG
Bexion Pharmaceuticals, LLC.
BIND Therapeutics, Inc.
Bio-Path Holdings, Inc.
BioDiem Ltd
Bionovis SA
Biotest AG
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
CEL-SCI Corporation
Celgene Corporation
Cell Medica Limited
Cellceutix Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Centrose LLC
Cristal Therapeutics
Critical Outcome Technologies Inc.
CTI BioPharma Corp.
CytomX Therapeutics, Inc.
Daiichi Sankyo Company, Limited
EcoBiotics Limited
Eisai Co., Ltd.
Eli Lilly and Company
EntreChem, S.L.
Etubics Corporation
Eureka Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
G&E Herbal Biotechnology Co., Ltd.
Genelux Corporation
Genentech, Inc.
Genexine, Inc.
Genmab A/S
Genticel S.A.
GlaxoSmithKline Plc
Gliknik, Inc.
Glycotope GmbH
Green Cross Corporation
Hanmi Pharmaceuticals, Co. Ltd.
HEC Pharm Co., Ltd.
Horizon Pharma Plc
Ignyta, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Immunovaccine, Inc.
Immunovative Therapies, Ltd.
Incyte Corporation
Innate Pharma SA
Inovio Pharmaceuticals, Inc.
InteRNA Technologies B.V.
IRX Therapeutics, Inc.
ISA Pharmaceuticals B.V.
ISU ABXIS Co.,Ltd.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Kolltan Pharmaceuticals, Inc.
Laboratoires Pierre Fabre SA
Loxo Oncology, Inc.
Lytix Biopharma AS
Mabion SA
Mabtech Limited
MacroGenics, Inc.
Marsala Biotech Inc.
Meabco A/S
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Molplex Ltd.
Multimmune GmbH
NanoCarrier Co., Ltd.
Natco Pharma Limited
Northwest Biotherapeutics, Inc.
Novartis AG
Omnitura Therapeutics Inc.
Oncobiologics, Inc.
Oncolys BioPharma Inc.
Oncolytics Biotech Inc.
Onconova Therapeutics, Inc.
OncoSec Medical Inc.
Ono Pharmaceutical Co., Ltd.
Orbis Biosciences, Inc.
Oryx GmbH & Co. KG
Otsuka Holdings Co., Ltd.
OXiGENE, Inc.
Panacea Biotec Limited
PCI Biotech AS
Pfizer Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
Pique Therapeutics
Plexxikon Inc.
PNP Therapeutics, Inc.
Profectus BioSciences, Inc.
Redx Pharma Plc
Sanofi
Sapvax
Sareum Holdings Plc
Selecta Biosciences, Inc.
Serina Therapeutics, Inc.
Shanghai Henlius Biotech Co., Ltd.
Shenzen SiBiono GeneTech Co., Ltd
Shionogi & Co., Ltd.
Silence Therapeutics Plc
Sillajen Biotherapeutics
Sinil Pharmaceutical Co., Ltd
Sorrento Therapeutics, Inc.
SuviCa Inc.
Symphogen A/S
Synta Pharmaceuticals Corp.
Taiwan Liposome Company, Ltd.
Takara Bio Inc.
Takis S.r.l.
Teva Pharmaceutical Industries Limited
Theravectys SA
Threshold Pharmaceuticals, Inc.
Tolero Pharmaceuticals, Inc.
Vaccibody AS
VasGene Therapeutics, Inc.
VentiRx Pharmaceuticals, Inc.
Virttu Biologics Limited
Viventia Bio Inc.
VLPbio
VM Discovery, Inc.
Zhejiang BetaPharma Co., Ltd.
Zymeworks Inc.
Zyngenia, Inc.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct